XML 50 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business combination - Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
6 Months Ended 13 Months Ended
Jun. 01, 2016
Jun. 30, 2017
Jun. 30, 2017
Dec. 31, 2016
[1]
Amounts Recognized        
Goodwill   $ 155,593 $ 155,593 $ 155,593
Licensed IP        
Amounts Recognized        
Weighted average useful life   12 years 6 months    
ARIAD Pharmaceuticals        
Amounts Recognized        
Current assets $ 21,413 $ 21,363 21,363  
Property and equipment 850 850 850  
Restricted cash 432 432 432  
Intangible assets 283,000 283,000 283,000  
Total identifiable assets 305,695 305,645 305,645  
Current liabilities (15,720) (15,538) (15,538)  
Other long term liabilities (5,226) (5,226) (5,226)  
Total liabilities assumed (20,946) (20,764) (20,764)  
Goodwill 155,725 155,593 155,593  
Total fair value of consideration transferred 440,474 $ 440,474 440,474  
Measurement Period Adjustments        
Current assets     (50)  
Total identifiable assets     (50)  
Current liabilities     182  
Total liabilities assumed     182  
Goodwill     $ (132)  
ARIAD Pharmaceuticals | Maximum        
Amounts Recognized        
Development costs $ 7,000      
ARIAD Pharmaceuticals | Licensed IP        
Amounts Recognized        
Discount rate (as a percent) 15.00%      
Gross margins (as a percent) 98.00%      
Weighted average useful life 12 years 6 months      
ARIAD Pharmaceuticals | Licensed IP | Minimum        
Amounts Recognized        
Tax rates (as a percent) 7.80%      
ARIAD Pharmaceuticals | Licensed IP | Maximum        
Amounts Recognized        
Tax rates (as a percent) 13.80%      
Development costs $ 7,000      
ARIAD Pharmaceuticals | IPR&D        
Amounts Recognized        
Probability of technical success (“PTS”) (as a percent) 25.00%      
Discount rate (as a percent) 16.00%      
Gross margins (as a percent) 98.00%      
ARIAD Pharmaceuticals | IPR&D | Minimum        
Amounts Recognized        
Tax rates (as a percent) 7.80%      
ARIAD Pharmaceuticals | IPR&D | Maximum        
Amounts Recognized        
Tax rates (as a percent) 13.80%      
[1] The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements at that date.